Skip to main content
. 2013 Jun 7;5:91–101. doi: 10.2147/CMAR.S32973

Table 2.

Clinical trials of crizotinib treatment for advanced non-small-cell lung cancer positive for anaplastic lymphoma kinase rearrangement

Phase Regimens Patients ORR (%) PFS (months) OS (months) References
I Crizotinib 149 60.8 9.7 Not achieved 79,89
II Crizotinib 261 59.8 8.1 Not achieved 91
III Crizotinib 172 65.7 7.7 20.3 90
Docetaxel 72 6.9 2.6 22.8
Pemetrexed 99 29.3 4.2

Abbreviations: PFS, progression-free survival; OS, overall survival; ORR, objective response rate.